Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2020-07-02 | APTO | Aptose Biosciences Inc. | Marango Jotin | SVP, Chief Bus. Officer | S - Sale | $6.34 | -20,946 | 179,054 | -10% | -$132,793 | ||||||
2020-07-01 | SGEN | Seattle Genetics Inc /wa | Simpson Todd E | CFO | S - Sale | $167.58 | -11,573 | 163,181 | -7% | -$1,939,352 | ||||||
| D | 2020-07-01 | HARP | Harpoon Therapeutics, Inc. | Wesche Holger | Chief Scientific Officer | S - Sale+OE | $16.20 | -10,000 | 52,669 | -16% | -$161,989 | |||||
| D | 2020-07-01 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Business Development Off | S - Sale+OE | $47.34 | -6,771 | 0 | -100% | -$320,540 | |||||
| D | 2020-07-01 | ADPT | Adaptive Biotechnologies Corp | Hill Nancy Louise | EVP, Operations, Program Mana | S - Sale+OE | $47.42 | -3,000 | 11,200 | -21% | -$142,266 | |||||
| D | 2020-07-01 | VIR | Vir Biotechnology, Inc. | Parrish Jay | Chief Business Officer | S - Sale+OE | $37.95 | -75,000 | 222,222 | -25% | -$2,846,310 | |||||
| D | 2020-07-01 | VIR | Vir Biotechnology, Inc. | Pang Phillip | Chief Medical Officer | S - Sale+OE | $37.78 | -12,500 | 15,777 | -44% | -$472,252 | |||||
| M | 2020-07-01 | VIR | Vir Biotechnology, Inc. | Horn Howard | CFO | S - Sale | $38.92 | -20,000 | 207,777 | -9% | -$778,399 | |||||
| D | 2020-06-30 | NK | Nantkwest, Inc. | Simon Barry J. | See remarks | S - Sale+OE | $13.00 | -9 | 3,170,540 | 0% | -$117 | |||||
2020-06-30 | NSTG | Nanostring Technologies Inc | Bailey K Thomas | CFO | S - Sale | $29.17 | -3,260 | 0 | -100% | -$95,105 | ||||||
| D | 2020-06-30 | FUSN | Fusion Pharmaceuticals Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | Former 10% Owner | P - Purchase | $17.00 | +250,000 | 4,853,588 | +5% | +$4,250,000 | |||||
2020-07-01 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $62.92 | -18,344 | 24,297,501 | 0% | -$1,154,204 | ||||||
| D | 2020-06-30 | MRNA | Moderna, Inc. | Zaks Tal Zvi | Chief Medical Officer | S - Sale+OE | $64.00 | -39,752 | 0 | -100% | -$2,544,294 | |||||
2020-07-01 | PTE | Polarityte, Inc. | Seaburg David B | CEO | S - Sale | $1.28 | -8,514 | 1,002,451 | -1% | -$10,881 | ||||||
2020-06-30 | FUSN | Fusion Pharmaceuticals Inc. | Preston Heather | Dir | P - Purchase | $17.00 | +8,823 | 8,823 | New | +$149,991 | ||||||
2020-06-30 | FUSN | Fusion Pharmaceuticals Inc. | O'Leary James J | Chief Medical Officer | P - Purchase | $17.00 | +300 | 300 | New | +$5,100 | ||||||
2020-06-30 | FUSN | Fusion Pharmaceuticals Inc. | Crowley John J | CFO | P - Purchase | $17.00 | +6,500 | 6,500 | New | +$110,500 | ||||||
| D | 2020-06-30 | FUSN | Fusion Pharmaceuticals Inc. | Khuong Chau Quang | Dir | P - Purchase | $17.00 | +898,000 | 192,100 | -127% | +$15,266,000 | |||||
| D | 2020-06-30 | FUSN | Fusion Pharmaceuticals Inc. | Healthcap Vii, L.P. | 10% | P - Purchase | $17.00 | +240,000 | 3,807,247 | +7% | +$4,080,000 | |||||
| D | 2020-06-30 | FUSN | Fusion Pharmaceuticals Inc. | Christenson Johan | Dir | P - Purchase | $17.00 | +240,000 | 3,807,247 | +7% | +$4,080,000 | |||||
| D | 2020-06-30 | FUSN | Fusion Pharmaceuticals Inc. | Orbimed Advisors LLC | Dir | P - Purchase | $17.00 | +898,000 | 3,122,770 | +40% | +$15,266,000 | |||||
| D | 2020-06-30 | MNTA | Momenta Pharmaceuticals Inc | Beltramello Jo Ann | Chief HR, Inf. Officer | S - Sale+OE | $35.10 | -6,812 | 61,069 | -10% | -$239,101 | |||||
| D | 2020-06-30 | MNTA | Momenta Pharmaceuticals Inc | Arroyo Santiago | SVP, Chief Medical Officer | S - Sale+OE | $35.10 | -6,812 | 45,538 | -13% | -$239,101 | |||||
| D | 2020-06-30 | MNTA | Momenta Pharmaceuticals Inc | Cieplinska Agnieszka | Chief Accounting Officer (PAO) | S - Sale+OE | $35.11 | -947 | 7,574 | -11% | -$33,249 | |||||
| D | 2020-06-30 | MNTA | Momenta Pharmaceuticals Inc | Kwon Young | Chief Financial, Bus. Officer | S - Sale+OE | $35.11 | -6,810 | 157,936 | -4% | -$239,099 | |||||
| D | 2020-06-30 | MNTA | Momenta Pharmaceuticals Inc | Carvajal Alejandra | GC | S - Sale+OE | $35.10 | -6,811 | 27,445 | -20% | -$239,066 | |||||
| D | 2020-06-30 | MNTA | Momenta Pharmaceuticals Inc | Fier Ian | Chief Mfg, Program Officer | S - Sale+OE | $35.10 | -6,811 | 24,123 | -22% | -$239,066 | |||||
| D | 2020-06-30 | MNTA | Momenta Pharmaceuticals Inc | Manning Anthony M. | Chief Scientific Officer | S - Sale+OE | $35.10 | -6,811 | 29,191 | -19% | -$239,066 | |||||
| D | 2020-06-30 | MNTA | Momenta Pharmaceuticals Inc | Wheeler Craig A | Pres, CEO | S - Sale+OE | $33.32 | -37,575 | 666,749 | -5% | -$1,251,999 | |||||
2020-06-30 | XFOR | X4 Pharmaceuticals, Inc | Mostafa Adam S. | See Remarks | S - Sale | $9.04 | -1,725 | 7,923 | -18% | -$15,594 | ||||||
| D | 2020-06-26 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Business Development Off | S - Sale+OE | $47.42 | -417 | 0 | -100% | -$19,774 | |||||
2020-06-29 | ADAP | Adaptimmune Therapeutics Plc | Wood Gavin | CFO | P - Purchase | $1.62 | +33,000 | 33,000 | New | +$53,460 | ||||||
| D | 2020-06-26 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Business Development Off | S - Sale+OE | $47.42 | -417 | 0 | -100% | -$19,774 | |||||
| M | 2020-06-26 | DNLI | Denali Therapeutics Inc. | Bratton Douglas K | 10% | S - Sale | $23.97 | -250,000 | 14,092,916 | -2% | -$5,993,052 | |||||
2020-06-26 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $60.65 | -11,046 | 24,315,845 | 0% | -$669,892 | ||||||
2020-06-25 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $67.00 | -10,000 | 24,326,891 | 0% | -$670,000 | ||||||
| DM | 2020-06-26 | VXRT | Vaxart, Inc. | Armistice Capital, LLC | Dir | S - Sale+OE | $9.67 | -27,612,053 | 291,046 | -99% | -$266,997,653 | |||||
2020-06-26 | TBIO | Translate Bio, Inc. | Baupost Group Llc/ma | 10% | P - Purchase | $22.00 | +500,000 | 18,044,239 | +3% | +$11,000,000 | ||||||
| M | 2020-06-26 | ALLO | Allogene Therapeutics, Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | 10% | S - Sale | $42.53 | -85,151 | 19,716,306 | 0% | -$3,621,601 | |||||
2020-06-29 | PTE | Polarityte, Inc. | Hoyler Cameron J. | Gen. Counsel, EVP | S - Sale | $1.44 | -936 | 622,184 | 0% | -$1,348 | ||||||
2020-06-29 | NK | Nantkwest, Inc. | Soon-Shiong Patrick | COB, CEO, 10% | P - Purchase | $12.12 | +3,710,000 | 69,944,890 | +6% | +$44,965,200 | ||||||
| M | 2020-05-27 | PSTI | Pluristem Therapeutics Inc | Clover Wolf Capital - Limited Partnership | 10% | P - Purchase | $7.61 | +700,449 | 3,211,760 | +28% | +$5,328,131 | |||||
2020-06-25 | VIR | Vir Biotechnology, Inc. | Horn Howard | CFO | S - Sale | $50.00 | -30,000 | 227,777 | -12% | -$1,500,000 | ||||||
| DM | 2020-06-24 | CRSP | Crispr Therapeutics AG | Klein Lawrence Otto | CBO, COO | S - Sale+OE | $75.88 | -70,000 | 20,000 | -78% | -$5,311,564 | |||||
2020-06-25 | ATRA | Atara Biotherapeutics, Inc. | Touchon Pascal | Pres, CEO | S - Sale | $12.92 | -12,135 | 264,844 | -4% | -$156,784 | ||||||
| A | 2020-01-03 | CDTX | Cidara Therapeutics, Inc. | Abdollahian Neil | Chief Business Officer | S - Sale | $3.42 | -940 | 50,308 | -2% | -$3,215 | |||||
| A | 2020-01-03 | CDTX | Cidara Therapeutics, Inc. | Daruwala Paul | COO | S - Sale | $3.42 | -940 | 52,592 | -2% | -$3,215 | |||||
| DM | 2020-06-23 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale+OE | $46.54 | -33,300 | 679 | -98% | -$1,549,813 | |||||
| D | 2020-06-24 | ADPT | Adaptive Biotechnologies Corp | Taylor Stacy L | SVP, GC | S - Sale+OE | $46.68 | -2,880 | 1,300 | -69% | -$134,438 | |||||
| DM | 2020-06-23 | APTO | Aptose Biosciences Inc. | Whitehead Warren | Dir | S - Sale+OE | $6.93 | -35,000 | 40,000 | -47% | -$242,550 | |||||
| M | 2020-06-23 | ALLO | Allogene Therapeutics, Inc. | Tpg Group Holdings (Sbs) Advisors, Inc. | 10% | S - Sale | $44.04 | -219,853 | 19,801,457 | -1% | -$9,682,651 | |||||
| D | 2020-06-23 | MRNA | Moderna, Inc. | Zaks Tal Zvi | Chief Medical Officer | S - Sale+OE | $63.71 | -39,752 | 0 | -100% | -$2,532,720 | |||||
| M | 2020-06-23 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale | $64.24 | -10,000 | 1,980,656 | -1% | -$642,444 | |||||
2020-06-24 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $63.25 | -9,000 | 24,336,891 | 0% | -$569,250 | ||||||
2020-06-23 | ALEC | Alector, Inc. | McGuire Terrance | Dir, 10% | S - Sale | $31.54 | -4,377 | 12,853,817 | 0% | -$138,063 | ||||||
| D | 2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% | P - Purchase | $20.00 | +1,000,000 | 2,252,913 | +80% | +$20,000,000 | |||||
2020-06-23 | ALEC | Alector, Inc. | Polaris Venture Management Co. Vi, L.L.C. | 10% | S - Sale | $31.54 | -4,377 | 12,853,817 | 0% | -$138,063 | ||||||
2020-06-24 | TCON | Tracon Pharmaceuticals, Inc. | Theuer Charles | Pres, CEO | P - Purchase | $1.90 | +9,895 | 71,714 | +16% | +$18,801 | ||||||
2020-06-23 | CRSP | Crispr Therapeutics AG | Novak Rodger | Pres | S - Sale | $75.00 | -50,000 | 698,007 | -7% | -$3,750,000 | ||||||
| D | 2020-06-23 | NBIX | Neurocrine Biosciences Inc | Roberts Eiry | Chief Medical Officer | S - Sale+OE | $130.00 | -5,000 | 9,416 | -35% | -$650,000 | |||||
| D | 2020-06-23 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $130.00 | -5,000 | 26,021 | -16% | -$650,000 | |||||
2020-06-23 | GILD | Gilead Sciences Inc | Rodriguez Javier | Dir | S - Sale | $75.50 | -189 | 0 | -100% | -$14,270 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Wirth Peter | Dir | P - Purchase | $0.00 | +63,299 | 127,665 | +98% | +$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Wirth Peter | Dir | S - Sale | $0.00 | -78,454 | 127,665 | -38% | -$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Kelly Patrick F. | Chief Medical Officer | P - Purchase | $0.00 | +42,959 | 42,959 | New | +$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Kelly Patrick F. | Chief Medical Officer | S - Sale | $0.00 | -64,288 | 42,959 | -60% | -$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Fanucci Marsha | Dir | P - Purchase | $0.00 | +52,532 | 52,532 | New | +$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Fanucci Marsha | Dir | S - Sale | $0.00 | -67,894 | 52,532 | -56% | -$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Clackson Timothy P | Dir | P - Purchase | $0.00 | +23,590 | 23,590 | New | +$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Clackson Timothy P | Dir | S - Sale | $0.00 | -35,067 | 23,590 | -60% | -$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Wadlinger Mary E. | See Remarks | P - Purchase | $0.00 | +115,575 | 115,575 | New | +$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Wadlinger Mary E. | See Remarks | S - Sale | $0.00 | -144,452 | 115,575 | -56% | -$0 | ||||||
| D | 2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Ra Capital Management, L.P. | 10% | P - Purchase | $20.00 | +4,000,000 | 9,011,651 | +80% | +$80,000,000 | |||||
| D | 2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Kolchinsky Peter | Dir, 10% | P - Purchase | $20.00 | +4,000,000 | 9,011,651 | +80% | +$80,000,000 | |||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Paoletti Paolo | Dir | P - Purchase | $0.00 | +45,553 | 45,553 | New | +$0 | ||||||
2020-06-23 | FMTX | Forma Therapeutics Holdings, Inc., | Paoletti Paolo | Dir | S - Sale | $0.00 | -59,361 | 45,553 | -57% | -$0 | ||||||
| DM | 2020-06-23 | VIR | Vir Biotechnology, Inc. | Virgin Herbert | EVP, Research, CSO | S - Sale+OE | $44.64 | -14,920 | 0 | -100% | -$666,058 | |||||
| M | 2020-06-22 | CRSP | Crispr Therapeutics AG | Bolzon Bradley J Phd | Dir | S - Sale | $73.93 | -20,000 | 4,183,064 | 0% | -$1,478,522 | |||||
| M | 2020-06-22 | CRSP | Crispr Therapeutics AG | Ho Tony W | EVP, Head of R, D | S - Sale | $75.04 | -7,158 | 33,747 | -17% | -$537,123 | |||||
| D | 2020-06-22 | KOD | Kodiak Sciences Inc. | Ehrlich Jason | See Remarks | S - Sale+OE | $60.54 | -6,950 | 31,284 | -18% | -$420,747 | |||||
| D | 2020-06-22 | CHRS | Coherus Biosciences, Inc. | Szela Mary T | Dir | S - Sale+OE | $17.58 | -54,997 | 0 | -100% | -$966,759 | |||||
2020-06-22 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $65.92 | -4,521 | 24,346,891 | 0% | -$298,024 | ||||||
| D | 2020-06-23 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $15.01 | -14,751 | 1,622 | -90% | -$221,413 | |||||
| DM | 2020-06-19 | NK | Nantkwest, Inc. | Simon Barry J. | See remarks | S - Sale+OE | $10.56 | -200,041 | 3,170,540 | -6% | -$2,112,950 | |||||
2020-06-19 | BCDA | Biocardia, Inc. | Allen Jim L. | Dir | P - Purchase | $2.10 | +142,850 | 668,384 | +27% | +$299,985 | ||||||
2020-06-19 | BCDA | Biocardia, Inc. | Blank Andrew Scott | Dir | P - Purchase | $2.10 | +142,850 | 269,523 | +113% | +$299,985 | ||||||
2020-06-19 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir, 10% | P - Purchase | $2.10 | +142,850 | 1,227,800 | +13% | +$299,985 | ||||||
| D | 2020-06-22 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale+OE | $45.85 | -33,132 | 1,778,180 | -2% | -$1,519,227 | |||||
| D | 2020-06-22 | ADPT | Adaptive Biotechnologies Corp | Hill Nancy Louise | EVP, Operations, Program Mana | S - Sale+OE | $45.22 | -19,000 | 11,200 | -63% | -$859,120 | |||||
| D | 2020-06-19 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Business Development Off | S - Sale+OE | $45.00 | -417 | 0 | -100% | -$18,765 | |||||
| D | 2020-06-22 | ADVM | Adverum Biotechnologies, Inc. | Gasmi Mehdi | Dir | S - Sale+OE | $25.06 | -23,605 | 274,442 | -8% | -$591,617 | |||||
| M | 2020-06-19 | DNLI | Denali Therapeutics Inc. | Bratton Douglas K | 10% | S - Sale | $24.72 | -255,000 | 14,342,916 | -2% | -$6,304,373 | |||||
2020-06-19 | VIR | Vir Biotechnology, Inc. | Horn Howard | CFO | S - Sale | $40.00 | -10,000 | 257,777 | -4% | -$400,000 | ||||||
| D | 2020-06-19 | VIR | Vir Biotechnology, Inc. | Virgin Herbert | EVP, Research, CSO | S - Sale+OE | $38.00 | -3,510 | 0 | -100% | -$133,384 | |||||
2020-06-19 | LIFE | Atyr Pharma Inc | Broadfoot Jill Marie | CFO | P - Purchase | $4.22 | +1,850 | 9,153 | +25% | +$7,807 | ||||||
2020-06-19 | LIFE | Atyr Pharma Inc | Shukla Sanjay | Pres, CEO | P - Purchase | $4.27 | +6,000 | 7,291 | +465% | +$25,620 | ||||||
| D | 2020-06-22 | BBI | Brickell Biotech, Inc. | Sklawer Andrew D | COO, Secretary | P - Purchase | $0.00 | +13,044 | 96,250 | +16% | +$0 | |||||
| D | 2020-06-22 | BBI | Brickell Biotech, Inc. | McAvoy David R. | GC, CCO | P - Purchase | $0.00 | +30,435 | 59,357 | +105% | +$0 | |||||
| D | 2020-06-22 | BBI | Brickell Biotech, Inc. | Chadha Deepak | Chief Research, Dev. Officer | P - Purchase | $0.00 | +26,087 | 46,717 | +126% | +$0 | |||||
| D | 2020-06-22 | BBI | Brickell Biotech, Inc. | Brown Robert Busard | CEO | P - Purchase | $0.00 | +86,957 | 216,659 | +67% | +$0 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |